John McDonough Biography and Net Worth

John McDonough serves as Non-Executive Chairman of the Board of the Company. He has served as our President and Chief Executive Officer and a member of our Board of Directors since November 2007. From 2003 to 2007, Mr. McDonough held various positions at Cytyc Corporation, a company engaged in the design, development, manufacturing and marketing of clinical products that focus on women’s health, where he ultimately served as President of Cytyc Development Corporation. Mr. McDonough received his B.S.B.A. from Stonehill College. Mr. McDonough’s extensive management experience as a senior executive and his diagnostic company experience contributed to our Board of Directors’ conclusion that he should serve as a director of our company.

What is John McDonough's net worth?: The estimated net worth of John McDonough is at least $14,204.56 as of January 23rd, 2020. Mr. McDonough owns 5,128 shares of T2 Biosystems stock worth more than $14,205 as of April 23rd. This net worth estimate does not reflect any other investments that Mr. McDonough may own. Learn More about John McDonough's net worth.
How do I contact John McDonough?: The corporate mailing address for Mr. McDonough and other T2 Biosystems executives is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. T2 Biosystems can also be reached via phone at (781) 761-4646 and via email at [email protected]. Learn More on John McDonough's contact information.
Has John McDonough been buying or selling shares of T2 Biosystems?: John McDonough has not been actively trading shares of T2 Biosystems during the last ninety days. Most recently, John Mcdonough sold 181 shares of the business's stock in a transaction on Thursday, July 1st. The shares were sold at an average price of $116.00, for a transaction totalling $20,996.00. Learn More on John McDonough's trading history.
Who are T2 Biosystems' active insiders?: T2 Biosystems' insider roster includes Michael Gibbs (General Counsel), Adrian Jones (Director), and John McDonough (Director). Learn More on T2 Biosystems' active insiders.
Are insiders buying or selling shares of T2 Biosystems?: During the last twelve months, insiders at the medical equipment provider sold shares 4 times. They sold a total of 229,708 shares worth more than $6,948,906.00. The most recent insider tranaction occured on September, 27th when Major Shareholder Group L.P. Cr sold 59,812 shares worth more than $1,136,428.00. Insiders at T2 Biosystems own 0.1% of the company. Learn More about insider trades at T2 Biosystems.
Information on this page was last updated on 9/27/2023.

John McDonough Insider Trading History at T2 Biosystems

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/1/2021	Sell	181	$116.00	$20,996.00
1/23/2020	Sell	574	$115.00	$66,010.00	5,128
2/11/2019	Sell	81	$336.00	$27,216.00	4,563
2/1/2019	Sell	143	$343.00	$49,049.00

John McDonough Buying and Selling Activity at T2 Biosystems

T2 Biosystems Company Overview

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Today's Range

Now: $2.72

$2.60

$2.96

50 Day Range

MA: $4.00

$2.72

$6.39

2 Week Range

Now: $2.72

$2.60

$70.00

Volume

354,971 shs

Average Volume

271,125 shs

Market Capitalization

$14.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.11

Global crypto currency reset (41 major banks signed up)

From Stansberry Research | Ad

Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...

Here's everything you need to know.